Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Marty who wrote (3298)	4/2/2001 3:04:33 PM
From: Jibacoa	Respond to of 52153

Any opinions on NABI ? They are building a manufacturing facility nearby in Boca Raton, FL. I don't know wether it is the result of the nasty general market or that the effect of their recent presentation at Salomon Smith Barney is wearing off, but the recent stock's price gains are also wearing off.<g> Commenting on Nabi's participation in the conference, David Gury stated, ``This provided an opportunity to reaffirm the many factors that distinguish Nabi and our commitment to the discovery, development and commercialization of specialty biopharmaceutical products to treat and prevent infectious and autoimmune diseases.'' Those factors include: The successful marketing of four specialty biopharmaceutical products through our own US-based sales force. In 2000, sales for these products increased to $73 million. Nabi's progress in developing an extensive product pipeline focused on a unique conjugate vaccine technology and related immune globulin based products. This development effort is initially targeted on products for the treatment of bacterial infections. Building on this core technology, other products are also under development, including a vaccine to treat nicotine addiction. Our commitment to expand Nabi's current clinical research and development activities through collaborations with pharmaceutical companies and other strategic alliances. Nabi's state-of-the-art immune globulin manufacturing facility in Boca Raton, Florida. We expect to bring this plant online in 2001, following FDA licensure. This will assure a strategic source of supply for currently marketed and pipeline products, including Nabi-HB(TM) [Hepatitis B Immune Globulin (Human)], Nabi® Altastaph(TM) [Staphylococcus aureus Immune Globulin Intravenous (Human)], and Civacir(TM) [Hepatitis C Immune Globulin (Human)]. An antibody collections operation that will increase in importance as it is transitioned into a strategically important source of raw materials for our developing specialty biopharmaceutical products business. I have been kind of curious to find out the basis for a "nicotine addiction vaccine".<g> At any rate, it is interesting that the insiders and institutions have reportedly been buying lately, that it has only $0.04 cash/share but the earnings are on the + side and apparently improving. From a near term basis, and in spite of today's down-gap the stock price is still holding above its averages: siliconinvestor.com And from a longer term perspective, the near term average is trying to cut above the longer term one(that looks good): siliconinvestor.com If the price can close above 6 1/4, it seems it has a good probability for a good % move, provided we can get a little cooperation from the "general market"'s presently nasty condition.<g> Bernard